Sigma-Aldrich Expands Position in Whole Genome Amplification
News Feb 20, 2006
Sigma-Aldrich has announced a licensing agreement with Rubicon Genomics that allows Sigma to offer GenomePlex® Whole Genome Amplification (WGA) kits to service providers.
Under this agreement, Sigma-Aldrich may sell GenomePlex kits to companies offering Whole Genome Amplification Services, thus expanding the service market to archived samples, FFPE and single cells.
Rubicon Genomics will retain all rights to WGA for molecular diagnostics, and will continue its existing service business.
"This licensing agreement enables Sigma-Aldrich to partner with service providers that offer genetic processing capabilities and expertise," said Keith Jolliff, Director of Strategic Marketing at Sigma-Aldrich.
"Market Research shows that thirty percent of customers are currently using service companies for WGA. However, service providers have been limited in their ability to amplify DNA from damaged or degraded sources, such as FFPE or archived samples, and from single cells."
"This agreement allows Sigma-Aldrich to more broadly share our enhancements of the GenomePlex technology to enable service providers to more effectively meet the needs of researchers."
In 2004 Sigma-Aldrich announced an exclusive licensing agreement with Rubicon Genomics to further develop and commercialize the GenomePlex WGA technology.
At that time, Rubicon Genomics retained all rights to WGA for molecular diagnostics and services. Sigma-Aldrich's success with the GenomePlex technology has led to the development of several kits that offer accurate amplification.
The latest addition to the product family is the GenomePlex Single Cell WGA Kit, which is designed to support whole genome amplification from a single cell and results in a million-fold amplification of genomic DNA.
GenomePlex is a proprietary amplification method based on random fragmentation of the genome into a series of overlapping, short templates.
The resulting shorter DNA strands are efficiently primed and amplified to generate a library of DNA fragments with defined 3' and 5' termini, or the OmniPlex® library.
This library is replicated using a linear, isothermal amplification in the initial stages, followed by a limited round of geometric (PCR) amplifications.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018